A prostate-specific membrane antigen-targeted nanoplatform for synergistic prostate cancer therapy through androgen receptor transcriptional repression and self-reinforcing chemodynamic pathway

Androgen receptor (AR) represents a pivotal molecular target in prostate cancer (PCa), rendering hormonal therapy a central role in clinical management. However, limited therapeutic efficacy is frequently observed due to AR overexpression, aberrant splicing, and metabolic reprogramming-mediated drug resistance. Herein, this study constructs MnS-GUL-CB839 (MGC) nanoplatform, which achieves efficient and targeted accumulation in PCa via active-targeting motif Glu-urea-Lys, potently downregulates the expression of AR and its splice variant AR-V7 , and reverses glutamine dependence. In acidic tumor microenvironment, MGC enables sustained release of manganese ions (Mn 2+ ), hydrogen sulfide (H 2 S) and the glutamine metabolism inhibitor CB839. Specifically, Mn 2+ represses transcription of AR and AR-V7 for AR signaling suppression. In parallel, H 2 S elevates intracellular hydrogen peroxide levels via inhibiting the catalytic activity of catalase, CB839 reverses glutamine addiction and diminishes glutathione production through inhibition of the rate-limiting enzyme in glutamine metabolism termed glutaminase 1. H 2 S and CB839 synergistically amplify Mn 2+ -catalyzed Fenton-like reactions, generating abundant hydroxyl radicals. Ultimately, this cascade realizes enhanced chemodynamic therapy (CDT) for ferroptosis and apoptosis induction. In summary, our findings underscore MGC as a promising nanoplatform to integrate AR signaling suppression, metabolic reprogramming and self-enhanced CDT, which establishes a unified therapeutic paradigm for PCa.

Authors

Institutions

Publication Details

Journal
Bioactive Materials
Published
2026-11-19
DOI
https://doi.org/10.1016/j.bioactmat.2026.10.036
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A prostate-specific membrane antigen-targeted nanoplatform for synergistic prostate cancer therapy through androgen receptor transcriptional repression and self-reinforcing chemodynamic pathway

Jialin Meng, Jun Zhou, Xiao Jun Sun, Guowen Jiang et al.
Bioactive Materials
Nanoplatforms for cancer theranostics
article

A prostate-specific membrane antigen-targeted nanoplatform for synergistic prostate cancer therapy through androgen receptor transcriptional repression and self-reinforcing chemodynamic pathway

Jialin Meng, Jun Zhou, Xiao Jun Sun, Guowen Jiang, Li Zhang, Wanqing Yang, Rui Tan, Zhaoxu Shi, Yunjiao Zhang, Wenrui Guan, Wanshui Yang, Chaozhao Liang, Liya Tian
article en

Abstract

Androgen receptor (AR) represents a pivotal molecular target in prostate cancer (PCa), rendering hormonal therapy a central role in clinical management. However, limited therapeutic efficacy is frequently observed due to AR overexpression, aberrant splicing, and metabolic reprogramming-mediated drug resistance. Herein, this study constructs MnS-GUL-CB839 (MGC) nanoplatform, which achieves efficient and targeted accumulation in PCa via active-targeting motif Glu-urea-Lys, potently downregulates the expression of AR and its splice variant AR-V7 , and reverses glutamine dependence. In acidic tumor microenvironment, MGC enables sustained release of manganese ions (Mn 2+ ), hydrogen sulfide (H 2 S) and the glutamine metabolism inhibitor CB839. Specifically, Mn 2+ represses transcription of AR and AR-V7 for AR signaling suppression. In parallel, H 2 S elevates intracellular hydrogen peroxide levels via inhibiting the catalytic activity of catalase, CB839 reverses glutamine addiction and diminishes glutathione production through inhibition of the rate-limiting enzyme in glutamine metabolism termed glutaminase 1. H 2 S and CB839 synergistically amplify Mn 2+ -catalyzed Fenton-like reactions, generating abundant hydroxyl radicals. Ultimately, this cascade realizes enhanced chemodynamic therapy (CDT) for ferroptosis and apoptosis induction. In summary, our findings underscore MGC as a promising nanoplatform to integrate AR signaling suppression, metabolic reprogramming and self-enhanced CDT, which establishes a unified therapeutic paradigm for PCa.

Bioactive MaterialsVol. 70
Anhui Medical University (CN), Shandong Tumor Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), Shandong First Medical University (CN), South China University of Technology (CN)
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon